Indivior agrees license deal and files for US approval for RBP-7000

Californian biotech DURECT and the UK’s Indivior have agreed a licensing deal related to RBP-7000, an investigational once-monthly injectable risperidone product.

At the same time, the British firm announced it has filed for regulatory approval in the USA for the drug, as a schizophrenia treatment.

Indivior has paid out $12.5 million, and is subject to pay quarterly earn-out payments that are based on a single digit percentage of US net sales for certain products covered by the patent rights, including RBP-7000.

The patent rights include granted patents extending through at least 2026.